Janus kinase (JAK) inhibitors led to improvement of uveitis in approximately half of pediatric patients previously treated with disease-modifying antirheumatic drugs (DMARDs) in a case series.

They’ve been approved for the US market since 2012, but Janus kinase (JAK) inhibitors are still the new kid on the block in terms of rheumatoid arthritis treatment. As such, the real-world evidence on ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since ...

CHICAGO -- Hitting rheumatoid arthritis (RA) early and hard, with targeted therapies as first-line treatment, appears to ...

A meta-analysis reveals that oral Janus kinase inhibitors elevate LDL and HDL cholesterol, underscoring the need for lipid monitoring in patients receiving JAK inhibitor therapy.

JAK inhibitors like baricitinib, ritlecitinib, and brepocitinib show promise in treating alopecia areata, with baricitinib approved by FDA and EMA. Baricitinib significantly reduced SALT scores at 24 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. JAK inhibitors inhibit a broader cytokine profile than ...

Janus kinase (JAK) inhibitors are not only efficacious in terms of skin disease improvement, but also in terms of itch management, explained Mona Shahriari, MD, assistant clinical professor of ...

Over the past decade, patients with moderate to severe rheumatoid arthritis who have not had success with established treatments have been able to turn to a new class of drugs called Janus kinase (JAK ...

Switching to a second-line Janus kinase (JAK) inhibitor resulted in steroid-free clinical remission in about half of the patients with active ulcerative colitis (UC) after induction; compared with ...

Please provide your email address to receive an email when new articles are posted on . Acne was an adverse event for 6.2% of patients treated with Janus kinase (JAK) inhibitors vs. 1.3% of controls.